3191 results for «684»
3191 results
New evidence for treatment of calcified coronary artery disease
20 May 2025 – From EuroPCR 2025
Explore the latest randomized trials and studies advancing the treatment of calcified coronary artery disease. This session covers cutting balloon use, lithotripsy versus conventional preparation, and one-year outcomes comparing rotational atherectomy, lithotripsy, and laser. Also highlighted is the EMPOWER CAD study focusing on women treated with...
How to deal with secondary mitral regurgitation in 2025?
20 May 2025 – From EuroPCR 2025
Delve into the evolving management of secondary mitral regurgitation, and the critical role of the Heart Team. This session replay presents the latest clinical trials, treatment guidelines, and a case-based discussion covering medical and interventional strategies, heart failure optimization, frailty assessment, and advanced imaging techniques.
Valve-in-valve and coronary protection
11 Sep 2025 – From PCR Rio Valves 2025
Explore complex valve-in-valve procedures and coronary protection strategies through a series of challenging case presentations. Topics include management of high-risk valve-in-valve scenarios, strategies for degenerated aortic bioprostheses, innovative transcarotid approaches, fenestration stenting for late coronary obstruction, and analysis of valve embolisation events, providing valuable insights for...
Novelties on how to manage difficult TAVI situations
11 Sep 2025 – From PCR Rio Valves 2025
Stay at the forefront of TAVI management with this session highlighting novel approaches to difficult clinical scenarios. Topics include predictive scoring for pacemaker implantation, impact of baseline frailty on recovery, comparative imaging for coronary stenosis evaluation, physiology-guided PCI in TAVI patients, and outcomes of extrathoracic non-transfemoral...
Tailored transfemoral TAVI in complex anatomies - LIVE Case
11 Sep 2025 – From PCR Rio Valves 2025
Supported by an unrestricted educational grant from Medtronic
An 89-year-old male with hypertension, dyslipidemia, current smoking, stage III kidney disease, and a history of diagonal PCI in 2010 presented with severe symptomatic aortic stenosis and a small annulus (410 mm²), with RBBB on ECG.
Via bilateral femoral access,...
Mitral valve - How to evaluate?
11 Sep 2025 – From PCR Rio Valves 2025
This educational session focuses on comprehensive evaluation of the mitral valve to guide clinical decision-making. Topics include risk stratification and patient selection for Mitral TEER, detailed anatomy review, assessment of primary and secondary mitral regurgitation phenotypes, advanced quantification techniques per current guidelines, and pre-intervention transoesophageal echocardiography...
Management of mitral regurgitation patients undergoing TMVI screening
13 Jan 2022
This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)
01 Apr 2025
Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.
Author
PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial
18 May 2021
Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...
30 years of primary PCI – a tale of perseverance
16 May 2023
Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.
Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial
05 Mar 2023
Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.
Author
